A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was found to be effective against a specific genetic subtype of acute myeloid leukemia (AML) in a Phase Ib/II trial.
from Health & Medicine News -- ScienceDaily https://www.sciencedaily.com/releases/2020/05/200528160528.htm
No comments:
Post a Comment